PriceTargets.com logo

Bicara Therapeutics - BCAX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.20
  • Forecasted Upside: 158.39%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$15.95 As of 03/10/2025 02:11 PM ET
▼ -0.605 (-3.66%)

This chart shows the closing price for BCAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$16.55Closing price on 03/09/25:
Get New Bicara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCAX

Analyst Price Target is $41.20
▲ +158.39% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Bicara Therapeutics in the last 3 months. The average price target is $41.20, with a high forecast of $48.00 and a low forecast of $31.00. The average price target represents a 158.39% upside from the last price of $15.95.

This chart shows the closing price for BCAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
9/2412/243/253/26$8.12$18$28$38$48Closing price on 03/09/25: $16.55High$48.00Average$41.20Low$31.00




Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Bicara Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/16/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/8/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/12/2025WedbushReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
2/6/2025WedbushInitiated CoverageOutperform$31.00
2/5/2025WedbushUpgradeStrong-Buy
1/27/2025HC WainwrightBoost TargetBuy ➝ Buy$42.00 ➝ $45.00
12/6/2024HC WainwrightInitiated CoverageBuy$42.00
11/5/2024RODMAN&RENSHAWUpgradeStrong-Buy
11/5/2024Rodman & RenshawInitiated CoverageBuy$48.00
10/8/2024Cantor FitzgeraldInitiated CoverageOverweight
10/8/2024Morgan StanleyInitiated CoverageOverweight$35.00
10/8/2024TD CowenInitiated CoverageBuy
10/8/2024Stifel NicolausInitiated CoverageBuy$47.00
(Data available from 3/10/2020 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/12/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/11/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/11/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/10/2024
  • 16 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/9/2025
  • 5 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
2/8/2025
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2025

Current Sentiment

  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Bicara Therapeutics logo
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $15.95
Low: $15.78
High: $16.59

50 Day Range

MA: $13.53
Low: $11.60
High: $17.42

52 Week Range

Now: $15.95
Low: $11.10
High: $28.09

Volume

140,936 shs

Average Volume

369,638 shs

Market Capitalization

$867.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bicara Therapeutics?

The following Wall Street sell-side analysts have issued reports on Bicara Therapeutics in the last twelve months: Cantor Fitzgerald, HC Wainwright, Morgan Stanley, Rodman & Renshaw, RODMAN&RENSHAW, Stifel Nicolaus, TD Cowen, and Wedbush.
View the latest analyst ratings for BCAX.

What is the current price target for Bicara Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Bicara Therapeutics in the last year. Their average twelve-month price target is $41.20, suggesting a possible upside of 158.4%. Rodman & Renshaw has the highest price target set, predicting BCAX will reach $48.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $31.00 for Bicara Therapeutics in the next year.
View the latest price targets for BCAX.

What is the current consensus analyst rating for Bicara Therapeutics?

Bicara Therapeutics currently has 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCAX will outperform the market and that investors should add to their positions of Bicara Therapeutics.
View the latest ratings for BCAX.

What other companies compete with Bicara Therapeutics?

Other companies that are similar to Bicara Therapeutics include Xenon Pharmaceuticals, Amneal Pharmaceuticals, Catalyst Pharmaceuticals, Bausch Health Companies and Recursion Pharmaceuticals. Learn More about companies similar to Bicara Therapeutics.

How do I contact Bicara Therapeutics' investor relations team?

Bicara Therapeutics' physical mailing address is 116 Huntington Avenue, Suite 703, Boston, MA 02116, United States. The company's listed phone number is (617) 468-4219 and its investor relations email address is ir@bicara.com. The official website for Bicara Therapeutics is www.bicara.com. Learn More about contacing Bicara Therapeutics investor relations.





Receive Bicara Therapeutics News & Ratings Daily
Sign up to receive the latest news and ratings for Bicara Therapeutics and its competitors with PriceTargets.com’s free daily newsletter.